KRSA
Cyclerion Therapeutics, Inc.
There isn't enough reported data to score KRSA yet.
KRSA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KRSA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
KRSA PE Valuation
KRSA has no meaningful PE right now: it lost money over the past year.
KRSA Forward outlook
There aren't enough analyst estimates for KRSA to show an outlook.
KRSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.36 | -$7.18 |
| Q2 2026 | -$11.27 | -$6.16 |
| Q1 2026 | -$9.17 | -$1.12 |
| Q4 2025 | -$7.77 | +$0.70 |
| Q3 2025 | -$5.18 | +$9.16 |
| Q2 2025 | -$5.11 | -176% |
| Q1 2025 | -$8.05 | -$5.68 |
| Q4 2024 | -$8.47 | +$11.96 |
KRSA lost $12.36 per share over the past year, and its loss has widened in each of the last five quarters.
KRSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $1M | -43% |
| Q3 2025 | $875K | +351% |
| Q4 2022 | $608K | +14% |
| Q2 2022 | $306K | -90% |
| Q1 2022 | $711K | +1047% |
| Q4 2021 | $533K | +301% |
| Q3 2021 | $348K | -13% |
| Q2 2021 | $3M | +301% |
KRSA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -82% | -110 points |
| Q3 2025 | -115% | +467 points |
| Q2 2025 | -1798% | N/A |
| Q1 2025 | -1799% | N/A |
| Q4 2024 | 28% | N/A |
| Q3 2024 | -581% | N/A |
| Q4 2022 | -1209% | +1482 points |
| Q2 2022 | -4390% | -3851 points |
KRSA's operating margin was −82% last quarter, down 110 points from the same quarter a year ago.
KRSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.1M | -$46.8M |
| Q2 2026 | -$1.4M | -$929K |
| Q1 2026 | -$1.2M | -$274K |
| Q4 2025 | -$1.6M | -539% |
| Q3 2025 | -$264K | +$1.5M |
| Q2 2025 | -$503K | +$603K |
| Q1 2025 | -$968K | +$903K |
| Q4 2024 | $360K | +$1.9M |
KRSA has burned cash in almost every quarter: −$51M over the past year, against −$1M the year before.
KRSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2127% | +12.9M shares |
| 1 year | +2983% | +13.1M shares |
| 3 years | +4049% | +13.2M shares |
| 5 years | +5456% | +13.3M shares |
KRSA has 14M diluted shares, up 2983% from a year ago.
KRSA Net Leverage
KRSA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KRSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 63.2 | Neutral |
KRSA's weekly RSI is 58 (neutral) and its Stochastic is 63 (neutral).
KRSA PE vs Healthcare Sector
| Metric | KRSA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRSA has no meaningful PE right now: it lost money over the past year.
KRSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 0.5% below |
| 20 week MA | $28.9 | 8.2% above |
| 50 week MA | $21.1 | 48% above |
| 100 week MA | $20.1 | 55% above |
| 200 week MA | $25.3 | 24% above |
KRSA has slipped below its 8-week average, but it's still above the other four, and 24% above its 200-week average.
KRSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $355.6 | $436.8 | +23% |
| 2021 | $436.8 | $245.0 | -44% |
| 2022 | $245.0 | $76.4 | -69% |
| 2023 | $76.4 | $23.5 | -69% |
| 2024 | $23.5 | $23.1 | -1.5% |
| 2025 | $23.1 | $9.45 | -59% |
| 2026 YTD | $9.45 | $31.3 | +231% |
KRSA has finished five years in a row lower, and it's up 231% so far in 2026.